Cesar Gentille
Researcher
Also affiliated: Houston Methodist (2020); University of Arkansas Medical Center (2025); Winthrop Rockefeller Foundation (2025); Stanford University (2021–2022)
Unknown Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Cesar Gentille's research focuses on hematologic malignancies and their treatments, particularly in the context of novel immunotherapies and chemotherapy regimens. His work investigates complications arising from treatments such as CAR-T cell therapy and bispecific T-cell engagers, examining outcomes in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Gentille has also studied the incidence and impact of opportunistic infections in patients undergoing daratumumab treatment for multiple myeloma and explored the use of isotretinoin in acute promyelocytic leukemia. His research further addresses the identification and surveillance of cardiotoxicity associated with targeted cancer immunotherapies, specifically cytokine release syndrome as a trigger for detecting cardiac dysfunction post-CAR-T therapy. Gentille also contributes to understanding the efficacy of treatments like mogamulizumab in relapsed and refractory Sézary syndrome.
Metrics
- h-index: 1
- Publications: 9
- Citations: 13
Selected Publications
-
Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report (2026)
-
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)
-
Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome (2025)
Collaboration Network
Top Collaborators
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
- Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
- Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL
- Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report
- Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report
- Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report
Similar Researchers
Based on overlapping research topics